BioReperia

Executive Summary

BioReperia is a Swedish pre-clinical stage company developing the ZTX platform, a humanized in-vivo oncology drug development tool that addresses key challenges in clinical cancer diagnostics and drug development. By providing a more physiologically relevant model, ZTX aims to improve predictivity and reduce attrition rates in oncology drug discovery. The platform has the potential to transform preclinical testing by enabling better translation of therapeutic efficacy and safety from animals to humans. Despite being in early stages, BioReperia's innovative approach positions it well within the proteomics and diagnostics ecosystem, with opportunities for collaborations with pharmaceutical companies seeking to optimize their drug development pipelines. The company's progress hinges on successful validation studies and securing partnerships or funding to advance its platform towards clinical application.

Upcoming Catalysts (preview)

• Q3 2026Presentation of initial in vivo validation data for ZTX platform60% success
• Q4 2026Securing strategic partnership with major pharma for co-development30% success
• Q1 2027Completion of Series A funding round40% success